Anika Therapeutics Reports Mixed Q2 Results with Promising Growth in Regenerative Solutions
Anika Therapeutics Inc. reported a mixed financial performance in Q2 2025, with a revenue decline of 8%, but showed promising growth in its Regenerative Solutions segment and key product lines.
2 minutes to read